|
1
|
Li J, Yang S, Su N, Wang Y, Yu J, Qiu H
and He X: Overexpression of long non-coding RNA HOTAIR leads to
chemoresistance by activating the Wnt/β-catenin pathway in human
ovarian cancer. Tumour Biol. 37:2057–2065. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Musella A, Marchetti C, Palaia I, Perniola
G, Giorgini M, Lecce F, Vertechy L, Iadarola R, De Felice F, Monti
M, et al: Secondary cytoreduction in Platinum-resistant recurrent
ovarian cancer: A Single-institution experience. Ann Surg Oncol.
22:4211–4216. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gabra H: Introduction to managing patients
with recurrent ovarian cancer. EJC Suppl. 12:2–6. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Du XL, Parikh RC, Lairson DR, Giordano SH
and Cen P: Comparative effectiveness of platinum-based chemotherapy
versus taxane and other regimens for ovarian cancer. Med Oncol.
30:4402013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pinato DJ, Graham J, Gabra H and Sharma R:
Evolving concepts in the management of drug resistant ovarian
cancer: Dose dense chemotherapy and the reversal of clinical
platinum resistance. Cancer Treat Rev. 39:153–160. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vendetti FP, Lau A, Schamus S, Conrads TP,
O'Connor MJ and Bakkenist CJ: The orally active and bioavailable
ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of
cisplatin to resolve ATM-deficient non-small cell lung cancer in
vivo. Oncotarget. 6:44289–44305. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhu S, Pabla N, Tang C, He L and Dong Z:
DNA damage response in cisplatin-induced nephrotoxicity. Arch
Toxicol. 89:2197–2205. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang L, Mosel AJ, Oakley GG and Peng A:
Deficient DNA damage signaling leads to chemoresistance to
cisplatin in oral cancer. Mol Cancer Ther. 11:2401–2409. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schiewer MJ, Goodwin JF, Han S, Brenner
JC, Augello MA, Dean JL, Liu F, Planck JL, Ravindranathan P,
Chinnaiyan AM, et al: Dual roles of PARP-1 promote cancer growth
and progression. Cancer Discov. 2:1134–1149. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Johannessen TC, Prestegarden L, Grudic A,
Hegi ME, Tysnes BB and Bjerkvig R: The DNA repair protein ALKBH2
mediates temozolomide resistance in human glioblastoma cells. Neuro
Oncol. 15:269–278. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lai TC, Chow KC, Lin TY, Chiang IP, Fang
HY, Chen CY and Ho SP: Expression of 53BP1 as a cisplatin-resistant
marker in patients with lung adenocarcinomas. Oncol Rep.
24:321–328. 2010.PubMed/NCBI
|
|
12
|
Zhu B, Block NL and Lokeshwar BL:
Interaction between stromal cells and tumor cells induces
chemoresistance and matrix metalloproteinase secretion. Ann N Y
Acad Sci. 878:642–646. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fukuda T, Wu W, Okada M, Maeda I, Kojima
Y, Hayami R, Miyoshi Y, Tsugawa K and Ohta T: Class I histone
deacetylase inhibitors inhibit the retention of BRCA1 and 53BP1 at
the site of DNA damage. Cancer Sci. 106:1050–1056. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li J and Xu X: DNA double-strand break
repair: A tale of pathway choices. Acta Biochim Biophys Sin
(Shanghai). 48:641–646. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zimmermann M and de Lange T: 53BP1: Pro
choice in DNA repair. Trends Cell Biol. 24:108–117. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schultz LB, Chehab NH, Malikzay A and
Halazonetis TD: p53 binding protein 1 (53BP1) is an early
participant in the cellular response to DNA double-strand breaks. J
Cell Biol. 151:1381–1390. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rappold I, Iwabuchi K, Date T and Chen J:
Tumor suppressor p53 binding protein 1 (53BP1) is involved in DNA
damage-signaling pathways. J Cell Biol. 153:613–620. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chai YL, Cui J, Shao N, Shyam E, Reddy P
and Rao VN: The second BRCT domain of BRCA1 proteins interacts with
p53 and stimulates transcription from the p21WAF1/CIP1 promoter.
Oncogene. 18:263–268. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Markova E, Vasilyev S and Belyaev I: 53BP1
foci as a marker of tumor cell radiosensitivity. Neoplasma.
62:770–776. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Morales JC, Xia Z, Lu T, Aldrich MB, Wang
B, Rosales C, Kellems RE, Hittelman WN, Elledge SJ and Carpenter
PB: Role for the BRCA1 C-terminal repeats (BRCT) protein 53BP1 in
maintaining genomic stability. J Biol Chem. 278:14971–14977. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hong S, Li X, Zhao Y, Yang Q and Kong B:
53BP1 suppresses tumor growth and promotes susceptibility to
apoptosis of ovarian cancer cells through modulation of the Akt
pathway. Oncol Rep. 27:1251–1257. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fischer KR, Durrans A, Lee S, Sheng J, Li
F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J, et al:
Epithelial-to-mesenchymal transition is not required for lung
metastasis but contributes to chemoresistance. Nature. 527:472–476.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Christiansen JJ and Rajasekaran AK:
Reassessing epithelial to mesenchymal transition as a prerequisite
for carcinoma invasion and metastasis. Cancer Res. 66:8319–8326.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nicolson GL: Tumor and host molecules
important in the organ preference of metastasis. Semin Cancer Biol.
2:143–154. 1991.PubMed/NCBI
|
|
26
|
Dass K, Ahmad A, Azmi AS, Sarkar SH and
Sarkar FH: Evolving role of uPA/uPAR system in human cancers.
Cancer Treat Rev. 34:122–136. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pârvănescu V, Georgescu M, Georgescu I,
Surlin V, Pâtrascu S, Picleanu AM and Georgescu E: The role of
matrix metalloproteinase-9 (MMP-9) as a prognostic factor in
epithelial and lymphatic neoplasia. Chirurgia (Bucur). 110:506–510.
2015.PubMed/NCBI
|
|
28
|
Lee JH, Chiang SY, Nam D, Chung WS, Lee J,
Na YS, Sethi G and Ahn KS: Capillarisin inhibits constitutive and
inducible STAT3 activation through induction of SHP-1 and SHP-2
tyrosine phosphatases. Cancer Lett. 345:140–148. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Michaud WA, Nichols AC, Mroz EA, Faquin
WC, Clark JR, Begum S, Westra WH, Wada H, Busse PM, Ellisen LW and
Rocco JW: Bcl-2 blocks cisplatin-induced apoptosis and predicts
poor outcome following chemoradiation treatment in advanced
oropharyngeal squamous cell carcinoma. Clin Cancer Res.
15:1645–1654. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhou BP, Liao Y, Xia W, Spohn B, Lee MH
and Hung MC: Cytoplasmic localization of p21Cip1/WAF1 by
Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat
Cell Biol. 3:245–252. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ghanem L and Steinman R: A Proapoptotic
function of p21 in differentiating granulocytes. Leuk Res.
29:1315–1323. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li X, Kong X, Kong X, Wang Y, Yan S and
Yang Q: 53BP1 sensitizes breast cancer cells to 5-fluorouracil.
PLoS One. 8:e749282013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pan S, Cheng L, White JT, Lu W, Utleg AG,
Yan X, Urban ND, Drescher CW, Hood L and Lin B: Quantitative
proteomics analysis integrated with microarray data reveals that
extracellular matrix proteins, catenins, and p53 binding protein 1
are important for chemotherapy response in ovarian cancers. OMICS.
13:345–354. 2009. View Article : Google Scholar : PubMed/NCBI
|
